Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.

People with HIV and fatty liver disease who were on INSTI drugs had similar body measurements at the start of the study compared to those not on INSTIs.

Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.

Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.